Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)

Tipranks - Tipranks - Wed Mar 25, 7:04AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD).

Claim 30% Off TipRanks Premium

Amgen (AMGN)

Scotiabank analyst Louise Chen maintained a Buy rating on Amgen today and set a price target of $385.00. The company’s shares closed last Monday at $349.77.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.5% and a 47.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Teva Pharmaceutical. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $366.70, a 4.2% upside from current levels. In a report issued on March 11, TD Cowen also maintained a Buy rating on the stock with a $420.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Apogee Therapeutics (APGE)

Truist Financial analyst Danielle Brill maintained a Hold rating on Apogee Therapeutics today. The company’s shares closed last Monday at $79.24.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 13.7% and a 51.8% success rate. Brill covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Centessa Pharmaceuticals, and Maze Therapeutics, Inc. ;'>

Apogee Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $120.60, a 56.0% upside from current levels. In a report released yesterday, TipRanks – xAI also reiterated a Hold rating on the stock with a $64.00 price target.

Gilead Sciences (GILD)

Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences today. The company’s shares closed last Monday at $137.34.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.8% and a 46.4% success rate. Renza covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Abivax SA Sponsored ADR, and Viridian Therapeutics. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $158.00, representing a 13.1% upside. In a report issued on March 10, Jefferies also initiated coverage with a Buy rating on the stock with a $180.00 price target.

Read More on AMGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).